×
About 189,672 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  87,209 results

Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration...
https://doi.org/10.2967/jnumed.120.258533
Journal of Nuclear Medicine : Official Publication, Socie... Treiber H, Koenig A et. al.

May 15th, 2021 - 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we des...

PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of d...
https://doi.org/10.2967/jnumed.121.262120
Journal of Nuclear Medicine : Official Publication, Socie... Barbato F, Fendler WP et. al.

May 15th, 2021 - Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework...

Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy ...
https://doi.org/10.1002/cam4.3932
Cancer Medicine; Getaneh AM, Heijnsdijk EA et. al.

May 15th, 2021 - The introduction of multiparametric magnetic resonance imaging (mpMRI) and MRI-guided biopsy has improved the diagnosis of prostate cancer. However, it remains uncertain whether it is cost-effective, especially in a population-based screening stra...

see more →

Guidelines  393 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  341 results see all →

Clinicaltrials.gov  94,995 results

Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration...
https://doi.org/10.2967/jnumed.120.258533
Journal of Nuclear Medicine : Official Publication, Socie... Treiber H, Koenig A et. al.

May 15th, 2021 - 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we des...

PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of d...
https://doi.org/10.2967/jnumed.121.262120
Journal of Nuclear Medicine : Official Publication, Socie... Barbato F, Fendler WP et. al.

May 15th, 2021 - Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework...

Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy ...
https://doi.org/10.1002/cam4.3932
Cancer Medicine; Getaneh AM, Heijnsdijk EA et. al.

May 15th, 2021 - The introduction of multiparametric magnetic resonance imaging (mpMRI) and MRI-guided biopsy has improved the diagnosis of prostate cancer. However, it remains uncertain whether it is cost-effective, especially in a population-based screening stra...

see more →

News  6,567 results

Freezing Breast Cancer to Death Avoids Surgery
https://www.medscape.com/viewarticle/950821

May 9th, 2021 - In the United States, cryoablation or freezing tissue to death is a primary treatment option for a variety of cancers, including those originating in or spread to the bone, cervix, eye, kidney, liver, lung, pancreas, prostate, and skin. Cryoablati...

Many Americans Put Off Cancer Screenings Because of COVID-19
https://www.medscape.com/viewarticle/950227

Apr 29th, 2021 - (Reuters Health) - Nearly 10 million screenings for three common cancers were missed in the U.S. because of the COVID-19 pandemic, a new study suggests. A comparison of monthly screening rates during the spring and summer of 2020 to rates during 2...

A New Frontier in Papillary Thyroid Cancer Treatment
https://www.medscape.com/viewarticle/949688

Apr 25th, 2021 - A 73-year-old man with prostate cancer and hypertension came to see me for an incidental diagnosis of papillary thyroid microcarcinoma (PTMC). He had undergone fluorodeoxyglucose (FDG) PET with his oncology team because of a rising serum prostate-...

Loss of MAP3K7 and CHD1 Expression Drive Recurrence, Resistance in Prostate Cancer
https://www.medscape.com/viewarticle/949819

Apr 25th, 2021 - NEW YORK (Reuters Health) - Loss of MAP3K7 protein expression, seen in approximately 40% of prostate cancer patients, is a major driver of prostate tumor aggressiveness and should be considered for inclusion in management algorithms, researchers s...

AHA Statement Flags CV Risk of Hormonal Cancer Therapies
https://www.medscape.com/viewarticle/949979

Apr 25th, 2021 - Hormonal therapies for the treatment of hormone-dependent breast and prostate cancer could raise the risk for myocardial infarction (MI) and stroke, and patients need to be closely monitored to allow early detection and treatment of cardiovascular...

see more →

Patient Education  167 results see all →